SG11201700774UA - Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor - Google Patents

Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Info

Publication number
SG11201700774UA
SG11201700774UA SG11201700774UA SG11201700774UA SG11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA
Authority
SG
Singapore
Prior art keywords
dlbcl
biomarkers
treatment
btk inhibitor
predicting response
Prior art date
Application number
SG11201700774UA
Inventor
Karl Schweighofer
Karl Eckert
Hsu-Ping Kuo
Betty Chang
Darrin Beaupre
Leo Cheung
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of SG11201700774UA publication Critical patent/SG11201700774UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4706Regulators; Modulating activity stimulating, promoting or activating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11201700774UA 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor SG11201700774UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462032430P 2014-08-01 2014-08-01
US201562119668P 2015-02-23 2015-02-23
US201562127484P 2015-03-03 2015-03-03
PCT/US2015/043300 WO2016019341A1 (en) 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Publications (1)

Publication Number Publication Date
SG11201700774UA true SG11201700774UA (en) 2017-02-27

Family

ID=55179406

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700774UA SG11201700774UA (en) 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Country Status (13)

Country Link
US (1) US20160032404A1 (en)
EP (1) EP3185870A4 (en)
JP (1) JP2017523188A (en)
KR (1) KR20170042614A (en)
CN (1) CN106714804A (en)
AU (1) AU2015296010A1 (en)
BR (1) BR112017001677A2 (en)
CA (1) CA2955744A1 (en)
IL (1) IL250221A0 (en)
MX (1) MX2017001302A (en)
RU (1) RU2017106794A (en)
SG (1) SG11201700774UA (en)
WO (1) WO2016019341A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
PT2350071E (en) 2008-10-22 2014-04-11 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc The use of inhibitors of bruton's tyrosine kinase (btk)
JP6575950B2 (en) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
NZ731909A (en) 2014-11-16 2023-11-24 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CR20180501A (en) 2016-04-04 2019-04-05 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PT3458456T (en) 2016-05-18 2020-12-07 Array Biopharma Inc Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
US11085039B2 (en) 2016-12-12 2021-08-10 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
JP7356351B2 (en) * 2016-12-12 2023-10-04 エクセラ・バイオサイエンシーズ・インコーポレイテッド Methods and systems for screening using microcapillary arrays
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
KR20200014418A (en) 2017-06-08 2020-02-10 엔리벡스 테라퓨틱스 리미티드 Therapeutic Apoptosis Cells for Cancer Therapy
CZ2017787A3 (en) 2017-12-08 2019-06-19 Zentiva, K.S. Pharmaceutical compositions containing ibrutinib
MA52874A (en) * 2018-06-15 2021-04-21 Janssen Pharmaceutica Nv FORMULATIONS / COMPOSITIONS INCLUDING IBRUTINIB
GB2577909B (en) * 2018-10-10 2020-11-18 Symetrica Ltd Gamma-ray spectrum classification
KR20210097160A (en) * 2018-11-30 2021-08-06 얀센 바이오테크 인코포레이티드 Methods of Treatment of Follicular Lymphoma
WO2021087044A1 (en) * 2019-10-30 2021-05-06 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
JP2024506855A (en) * 2021-02-03 2024-02-15 キュリス,インコーポレイテッド Biomarkers for fimepinostat therapy
WO2023275330A1 (en) * 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
KR20240027767A (en) * 2021-06-30 2024-03-04 얀센 파마슈티카 엔브이 Inhibitors of Bruton's Tyrosine Kinase and Methods of Using the Same
JP7423090B2 (en) * 2022-04-07 2024-01-29 学校法人藤田学園 B-cell lymphoma diagnostic aid kit and information provision method for patients with fever of unknown origin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575818A4 (en) * 2010-06-03 2013-11-06 Pharmacyclics Inc The use of inhibitors of bruton's tyrosine kinase (btk)
US20130102477A1 (en) * 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
EP2771010A4 (en) * 2011-10-19 2015-04-01 Pharmacyclics Inc Use of inhibitors of bruton's tyrosine kinase (btk)
WO2013063401A1 (en) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
KR20220093389A (en) * 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 Crystalline forms of a bruton's tyrosine kinase inhibitor
JP6575950B2 (en) * 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors
CN105142639A (en) * 2013-01-10 2015-12-09 林伯士艾瑞斯公司 IRAK inhibitors and uses thereof

Also Published As

Publication number Publication date
CN106714804A (en) 2017-05-24
JP2017523188A (en) 2017-08-17
WO2016019341A1 (en) 2016-02-04
IL250221A0 (en) 2017-03-30
MX2017001302A (en) 2017-10-11
RU2017106794A3 (en) 2019-02-27
AU2015296010A1 (en) 2017-02-02
US20160032404A1 (en) 2016-02-04
EP3185870A1 (en) 2017-07-05
CA2955744A1 (en) 2016-02-04
RU2017106794A (en) 2018-09-03
EP3185870A4 (en) 2018-06-20
BR112017001677A2 (en) 2018-07-17
KR20170042614A (en) 2017-04-19

Similar Documents

Publication Publication Date Title
IL250221A0 (en) Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
IL272130B (en) Inhibitors of lysine specific demethylase-1
HK1224202A1 (en) Primary carboxamides as btk inhibitors bik
CL2016002736A1 (en) Lysine specific demethylase-1 inhibitors
IL250876B (en) Inhibitors of lysine specific demethylase-1
IL249733B (en) Inhibitors of lysine specific demethylase-1
EP2948458A4 (en) Btk inhibitors
EP2948431A4 (en) Btk inhibitors
IL249876A0 (en) Inhibitors of lysine specific demethylase-1
EP3140427A4 (en) Biomarkers for response to pi3k inhibitors
DK3186242T3 (en) ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS
ZA201608555B (en) Biomarkers for response to ezh2 inhibitors
HK1231556A1 (en) Predictive method for determining tissual radiosensitivity
EP3176269A4 (en) Novel biomarker for predicting sensitivity to met inhibitor, and use thereof
SG10201800570RA (en) Biomarkers for assessing hiv
PT3126528T (en) Methods for determining responsiveness to mek/erk inhibitors
FR3018717B1 (en) MODEL FOR PREDICTING SURFACE RELEASE
IL252751A0 (en) Assays for btk inhibitors
GB201416375D0 (en) Analysis of cells on a substrate
GB201403199D0 (en) A method of identifying candidate compounds
TH1601002924A (en) New DGAT2 inhibitors
GB201421518D0 (en) Touch operation of a touch device
UA30271S (en) SET OF CASH FOR SHOES
TH1501006052A (en) BACEI inhibitors